THE VEHICLE LABORATORY

摘要

Many companies are realizing that the development of new delivery vehicles for therapeutics based on RNA interference (RNAi) will require collaborative efforts. "We view the delivery of small RNAs as one of the most important biomedical endeavours in modern biological science," says John Maraganore, chief executive of Alnylam Pharmaceuticals in Cambridge, Massachusetts. "And when you have such a broad-scale challenge and opportunity, you can't do everything internally — you have to work with the best groups outside as well."